A New Path to Drug Discovery
Bi-XDC technology empowers currently undruggable molecules and targets, transforming them into druggable entities. Designed to tackle substantial unmet medical needs in cancer and beyond, Bi-XDC offers a promising solution for advancing healthcare.
Coherent Biopharma
a company pioneering and developing Bi-targeting XDC technology
1 Proprietary Platform Technology
5+ First-in-Class Assets
15+ Global IP Protection
5+ Top scientists & industry experts.
110+ Expert professionals.
5 Potential First-in-Class
10+ Products
10+ Oncology Indication Clinical Trials
Integrated management organization in China, the U.S and Australia.
Breaking News
October 10, 2024 — Coherent Biopharma (“Coherent”) announced that the U.S. Food and Drug Administration (FDA) has grant...
On June 24, 2024, local time, the U.S. Food and Drug Administration (FDA) notified the approval of Orphan Drug Designation (ODD) f...
ASCO 2024 Highlights: Research findings of CBP-1008 and CBP-1018 once again attract global attention
The American Society of Clinical Oncology (ASCO) Annual Meeting 2024 held from May 31 to June 4 in Chicago, USA. At this year...